Intrahepatic cholestasis after liver transplantation

Liver Transplantation

Volumn 9, Issue 10, 2003, Pages 1005-1018

  Ben Ari, Ziv ^a   Pappo, Orit ^a   Mor, Eytan ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; GANCICLOVIR; INTERFERON; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PENTAMIDINE; RAPAMYCIN; RIBAVIRIN; S ADENOSYLMETHIONINE; TACROLIMUS; TAURODEOXYCHOLIC ACID; URSODEOXYCHOLIC ACID;

ACUTE GRAFT REJECTION; ARTERY THROMBOSIS; BACTERIAL INFECTION; BILE DUCT DISEASE; BILE DUCT OBSTRUCTION; BLOOD GROUP ABO INCOMPATIBILITY; CHRONIC GRAFT REJECTION; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG MEGADOSE; HEPATIC ARTERY; HUMAN; HYPERBILIRUBINEMIA; INTRAHEPATIC CHOLESTASIS; LIVER DYSFUNCTION; LIVER INJURY; LIVER TOXICITY; LIVER TRANSPLANTATION; LIVER VENOOCCLUSIVE DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PELIOSIS HEPATIS; PORTAL HYPERTENSION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RAT; RECURRENT DISEASE; REOPERATION; REPERFUSION INJURY; REVIEW; TREATMENT OUTCOME;

EID: 0142186208     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2003.50212     Document Type: Article

References (139)

1. Sherlock SH, Dooley J. Cholestasis. In: Sherlock SH, Dooley J, eds. Disease of the Liver and Biliary System. 11th ed. Oxford: Blackwell Scientific; 2002: 223.
2. Lee J, Boyer JL. Molecular alterations in hepatocyte transport mechanisms in acquired cholestatic liver disorders. Semin Liver Dis 2000;20:373-384.
3. Caldwell-Kenkel JC, Currin RT, Tanaka Y, Thurman RG, Lemasters JJ. Kupffer cell activation and endothelial cell damage after storage of rat livers: Effects of reperfusion. Hepatology 1991;13:83-95.
4. Reinders ME, van Wagensveld BA, van Gulik TM, Corssmit NP, Frederiks WM, Chamuleau RA, et al. No attenuation of ischemic and reperfusion injury in Kupffer cell-depleted, cold preserved rat livers. Transplantation 1997:63:449-454.
5. Kukan M, Vajdová K, Horecký J, Nagyová A, Mehendale HM, Tmovec T. Effects of blockade of Kupffer cells by gadolinium chloride on hepatobiliary function in cold ischemia-reperfusion injury of rat liver. Hepatology 1997;26:1250-1257.
6. Imamura H, Brault A, Huet P-M. Effects of extended cold preservation and transplantation on the rat liver microcirculation. Hepatology 1997;25:664-671.
7. McKeown CMB, Edwards V, Phillips MJ, Harvey PRC, Petrunka CN, Strasberg SM. Sinusoidal lining cell damage: The critical injury in cold preservation of liver allografts in the rat. Transplantation 1988;46:78-91.
8. Takei Y, Marzi I, Gao W, Gores GJ, Lemaster JJ, Thurman RG. Leukocyte adhesion and cell death after orthotopic liver transplantation in the rat. Transplantation 1991;51:959-965.
9. Clavien P-A, Harey PRC, Sanabria JR, Cywes R, Levy GA, Strasberg SM. Lymphocyte adherence in the reperfused rat liver: Mechanisms and effects. Hepatology 1993;17:131-142.
10. Cywes R, Packham MA, Tietze L, Sanabria JR, Harvey PR, Phillips MJ, Strasberg SM. Role of platelets in hepatic allograft preservation injury in the rat. Hepatology 1993;18:635-647.
11. Tredger JM. Ischemia-reperfusion injury of the liver, treatment in theory and in practice. Biofactors 1998;8:161-164.
12. Sanchez-Urdazpal L, Gores GJ, Ward EM, Maus TP, Buckel EG, Steers JL, et al. Diagnostic features and clinical outcome of ischemic-type biliary complications after liver transplantation. Hepatology 1993;17:605-609.
13. Tung BY, Kimmey MB. Biliary complications of orthotopic liver transplantation. Dig Dis 1999;17:133-144.
14. Adam R, Reynes M, Johann M, Morino M, Astarcioglu I, Kafetzis I, et al. The outcome of steatotic grafts in liver transplantation. Transplant Proc 1991;23:1538-1540.
15. Hui A-M, Kawasaki S, Makuuchi M, Nakayama J, Ikegami T, Miyagawa S. Liver injury after normothermic ischemia in steatotic rat liver. Hepatology 1995;20:1287-1293.
16. Sanchez-Urdazpal L, Gores GJ, Ward EM, Maus TP, Wahlstrom HE, Moore SB, et al. Ischemic-type biliary complications after orthotopic liver transplantation. Hepatology 1992;16:49-53.
17. Kadmon M, Bleyl J, Kueppers B, Otto G, Herfarth C. Biliary complications after prolonged University of Wisconsin preservation of liver allografts. Transplant Proc 1993;25:1651-1652.
18. Popescu I, Sheiner P, Mor E, Forman W, Borcich A, Emre S, et al. Biliary complications in 400 cases of liver transplantation. Mt Sinai J Med 1995;61:57-62.
19. Carrasco L, Sanchez-Buerno F, Sola J, Ruiz JM, Ramirez P, Robles R, et al. Effects of cold ischemia time on the graft after orthotopic liver transplantation. A bile cytological study. Transplantation 1996;61:393-396.
20. Noack K, Bronk SF, Kato A, Gores GJ. The greater vulnerability of bile duct cells to reoxygenation injury than to anoxia. Implications for the pathogenesis of biliary strictures after liver transplantation. Transplantation 1993;56:495-500.
21. Hertl M, Harvey PR, Swanson PE, West DD, Howard TK, Shenoy S, Strasberg SM.. Evidence of preservation injury to bile ducts by bile salts in the pig and its prevention by infusions of hydrophilic bile salts. Hepatology 1995;21:1130-1137.
22. Doctor RB, Dahl RH, Salter KD, Fouassier L, Chen J, Fitz JG. ATP depletion in rat cholangiocytes leads to marked internalization of membrane proteins. Hepatology 2000;31:1045-1054.
23. Totsuka E, Fung JJ, Ishii T, Urakami A, Moras NP, Hakamada K, et al. Influence of donor condition on postoperative graft survival and function in human liver transplantation. Transplant Proc 2000;32:322-326.
24. Curtin JC, Cantino D, Biasi F, Chiarpotto E, Salizzoni M, Andorno E, et al. Reperfusion damage to the bile canaliculi in the transplanted human liver. Hepatology 1996;24:1053-1057.
25. Neil DAH, Hubscher SG. Are parenchymal changes in early post-transplant biopsies related to preservation-reperfusion injury or rejection? Transplantation 2001;71:1566-1572.
26. Clavien PA, Harvey PRC, Strasberg SM. Preservation and reperfusion injuries in liver allografts: An overview and synthesis of current studies. Transplantation 1992;53:957-978.
27. Bennett-Guerrero E, Feierman DE, Barclay GR, Parides MK, Sheiner PA, Mythen MG, et al. Preoperative and intraoperative predictors of postoperative morbidity, poor graft function, and early rejection in 190 patients undergoing liver transplantation. Arch Surg 2001;136:1177-1183.
28. Yoo HY, Molmenti E, Thuluvath PJ. The effect of donor body mass index on primary graft nonfunction, retransplantation rate, and early graft and patient survival after liver transplantation. Liver Transpl 2003;9:72-978.
29. Azoulay D, Linhares M, Huguet E, Delvart V, Castaing D, Adam R, et al. Decision for retransplantation of the liver. An experience- and cost-based analysis. Ann Surg 2002;6:713-721.
30. Falasca L, Tisone G, Palmieri G, Anselmo A, Di Paolo D, Baiocchi L, et al. Protective role of tauroursodeoxycholate during harvesting and cold storage of human liver. Transplantation 20001;71:1268-1276.
31. Clavien PA. Sinusoidal endothelial cell injury during hepatic preservation and reperfusion. Hepatology 1988;28:281-285.
32. Vajdová K, Smreková R, Mislanova C, Kukan M, Lutterova M. Cold-preservation-induced sensitivity of rat hepatocyte function to rewarming injury and its prevention by short-term reperfusion. Hepatology 2000;32:289-296.
33. Dickson RC, Bronk SF, Gores GJ. Glycine cytoprotection during lethal hepatocellular injury from adenosine triphosphate depletion. Gastroenterology 1992;102:2098-2107.
34. Calmus Y, Cynober L, Dousset B, Lim SK, Soubrane O, Conti F, et al. Evidence for the detrimental role of proteolysis during liver preservation injury in humans. Gastroenterology 1995; 108:1510-1516.
35. Lanir A, Jankins RI, Caldwell C, Lee RG, Khettry U, Clouse ME. Hepatic transplantation survival: Correlation with adenine nucleotides levels in the donor liver. Hepatology 1988;8: 471-475.
36. Kusne S, Dummer JS, Singh N, Iwatsuki S, Makowka L, Esquivel C, et al. Infections after liver transplantation, an analysis of 100 consecutive cases. Medicine 1988;67:132-143.
37. Wade JJ, Rolando N, Hayllar K, Philpott-Howard J, Casewell MW, Williams R. Bacterial and fungal infections after liver transplantations: an analysis of 248 patients. Hepatology 1995; 21:1328-1336.
38. Singh N. Infectious diseases in the liver transplant recipient. Semin Gastrointest Dis 1998;9:136-146.
39. Moseley RH, Wang W, Takeda H, Lown K, Schick L, Ananthanarayanan M, Suchy FJ. Effects of endotoxin on bile acid transport in rat liver: A potential model for sepsis-associated cholestasis. Am J Physiol 1996;271:G137-G146.
40. Crawford JM. Cellular and molecular biology of the inflamed liver. Curr Opin Gastroenterol 1997;13:175-185.
41. Trauner M, Fickert P, Stauber R. Inflammation-induced cholestasis. J Gastroenterol Hepatol 1999;14:946-959.
42. Bolder U, Ton-Nu HT, Schteingart CD, Frick E, Hofmann AF. Hepatocyte transport of bile acids and organic anions in endotoxemic rats: Impaired uptake and secretion. Gastroenterology 1997;112:214-225.
43. Chang FY, Singh N, Gayowski T, Wagener MM, Marino IR. Fever in liver transplant recipients: Changing spectrum of etiologic agents. Clin Infec Dis 1998;26:59-65.
44. Lefkowitch JH. Bile ductular cholestasis: An ominous histopathologic sign related to sepsis and "cholangitis lenta." Hum Pathol 1982;13:19-24.
45. Rubin R, Munoz SJ, Moritz M. Rejection-independent cholangitis and cirrhosis after orthotopic liver transplantation. Hum Pathol 1993;24:996-1002.
46. Emre S, Soejima Y, Altaca G, Facciuto M, Fishbein TM, Sheiner PA, et al. Safety and risk of using pediatric donor livers in adult liver transplantation. Liver Transpl 2001;7:48-50.
47. Sugawara Y, Makuuchi M, Takayama T, Imamura H, Dowaki S, Mitzuta K, et al. Small-for-size grafts in living-related liver transplantation. J Am Coll Surg 2001;192:510-513.
48. Man K, Fan ST, Lo CM, Liu CL, Fung PC, Liang TB, et al. Graft injury in relation to graft size in right lobe live donor liver transplantation: A study of hepatic sinusoidal injury in correlation with portal hemodynamics and intragraft gene expression. Ann Surg 2003:237:256-264.
49. Demetris AJ, Ruppert K, Dvorchik I, Jain A, Minervini M, Nalesnik MA, et al. Real-time monitoring of acute liver-allograft rejection using the Banff schema. Transplantation 2002; 74:1290-1296.
50. Perkins JD, Rakela J, Sterioff S, Banks PM, Wiesner RH, Krom RA. Immunohistologic pattern of the portal T-lymphocyte infiltration in hepatic allograft rejection. Mayo Clin Proc 1989; 64:565-569.
51. Vierling JM, Fenell RH. Histopathology of early and late human hepatic allograft rejection: Evidence of progressive destruction of interlobular bile ducts. Hepatology 1985;5: 1076-1082.
52. Angermuller S, Steinmetz I, Weber T, Czerny F, Harnisch E, Kusterer K. Significant increase of Kupffer cells associated with loss of Na+, K+-ATPase activity in rat hepatic allograft rejection. Transplantation 1997;63:1562-1570.
53. Millis JM. Treatment of liver allograft rejection. Liver Transplant Surg 1999;5:S98-S106.
54. Neuberger J. Incidence, timing, and risk factors for acute and chronic rejection. Liver Transplant Surg 1999;5:S30-S36.
55. Singh N, Dummer JS, Kusne S, Breinig MK, Armstrong JA, Makowka L, et al. Infections with cytomegalovirus and other herpes viruses in 121 liver transplant recipients: Transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis 1988;158:124-131.
56. Mutimer D. CMV infection of transplant recipients. J Hepatol 1996;25:259-269.
57. Stratta RJ, Shaefer MS, Markin RS, Wood RP, Kennedy EM, Langnas AN, et al. Clinical patterns of cytomegalovirus disease after liver transplantation. Arch Surg 1989;124:1443-1449.
58. Lamps LW, Pinson CW, Raiford DS, Shyr Y, Scott MA, Washington MK. The significance of microabscesses in liver transplant biopsies: A clinicopathological study. Hepatology 1998; 28:1532-1537.
59. Martelius T, Krogerus L, Hockerstedt K, Bruggeman C, Lautenschlager I. Cytomegalovirus infection is associated with increased inflammation and severe bile duct damage in rat liver allografts. Hepatology 1998;27:996-1002.
60. Wiesner RH, Demetris AJ, Seaberg EC for the NIDDK Liver Transplantation Database. Chronic hepatic allograft rejection: Definition, risk factors and assessing impact on graft survival. Hepatology 1998;28:314A.
61. Arnold JC, Portmann BC, O'Grady JG, Naoumov NV, Alexander GJM, Williams R. Cytomegalovirus infection persists in the liver graft in the vanishing bile duct syndrome. Hepatology 1992;16:285-292.
62. Evans PC, Coleman N, Wreghitt TG, Wight DG, Alexander GJ. Cytomegalovirus infection of bile duct epithelial cells, hepatic artery and portal venous endothelium in relation to chronic rejection of liver grafts. J Hepatol 1999;31:913-920.
63. Wright TL. Cytomegalovirus infection and vanishing bile duct syndrome: Culprit or innocent bystander? Hepatology 1992; 16:494-496.
64. Kowdley KV, Keeffe EB. Hepatotoxicity of transplant immunosuppressive agents. Gastroenterol Clin North Am 1995;24: 991-1001.
65. Klintmalm GB, Iwatsuki S, Starzl TE. Cyclosporine A hepatotoxicity in 66 renal allograft recipients. Transplantation 1981; 32:488-489.
66. Lorber MI, Van Buren CT, Flechner SM, Williams C, Kahan BD. Hepatobiliary and pancreatic complications of cyclosporine therapy in 466 renal transplant recipients. Transplantation 1987;43:35-40.
67. Laupacis A, Keown PA, Ulan RA, Sinclair NR, Stiller CR. Hyperbilirubinemia and cyclosporine level. Lancet 1981;2: 1426-1427.
68. Chan FK, Shaffer EA. Cholestatic effects of cyclosporine in the rat. Transplantation 1997;63:1574-1578.
69. Kadmon M, Klunemann C, Bohme M, Ishikawa T, Gorgas K, Otto G, et al. Inhibition by cyclosporin A of adenosine triphosphate-dependent transport from the hepatocyte into bile. Gastroenterology 1993;104:1507-1514.
70. Moran D, De Buitrago JM, Fernandez E, Galan AJ, Munoz ME, Jimenez R. Inhibition of biliary glutathione secretion of cyclosporine A in the rat: Possible mechanisms and role in the cholestasis induced by the drug. J Hepatol 1998;29:68-77.
71. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 2000;118:422-430.
72. Cadranel JF, Erlinger S, Desruenne M, Luciani J, Lunel F, Grippon P, et al. Chronic administration of cyclosporin A induces a decrease in hepatic excretory function in man. Dig Dis Sci 1992;37:1473-1476.
73. Queneau PE, Bertault-Peres P, Guitaoui M, Mesdjian E, Durand A, Montet JC. Improvement of cyclosporin A-induced cholestasis by taurourosodeoxycholate in a long-term study in the rat. Dig Dis Sci 1994;39:1581-1585.
74. Fernandez E, Galan AI, Moran D, Gonzalez-Buitrago JM, Munoz ME, Jimenez R. Reversal of cyclosporin A-induced alterations in biliary secretion by S-adenosyl-L-methionine in rats. J Pharmacol Exp Ther 1995;275:442-449.
75. Sanchez-Campos S, Lopez-Acebo R, Gonzalez P, Culebras JM, Tunon MJ, Gonzalez-Gallego J. Cholestasis and alterations of glutathione metabolism induced by tacrolimus (FK506) in the rat. Transplantation 1998;66:84-88.
76. Ericzon BG, Eusufzai S, Soderdahl G, Duraj F, Einarsson K, Angelin B. Secretion and composition of bile after human liver transplantation: Studies on the effects of cyclosporine and tacrolimus. Transplantation 1997;63:74-80.
77. al-Quaiz MN, O'Grady JG, Tredger JM, Williams R. Variable effect of ursodeoxycholic acid on cyclosporine absorption after orthotopic liver transplantation. Transpl Int 1994;7:190-194.
78. Hebert MF, Ascher NL, Lake JR, Emond J, Nikolai B, Linna TJ, Roberts JP. Four-year follow-up of micophenolate mofetil for graft rescue in liver allograft recipients. Transplantation 1999;67:702-712.
79. Chang GJ, Mahanty HD, Quan D, Freise CE, Ascher NL, Roberts JP, et al. Experience with the use of sirolimus in liver transplantation - Use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl 2000;6:734-740.
80. Allison AC. Immunosuppressive drugs: The first 50 years and a glance forward. Immunopharmacology 2000;47:63-83.
81. Sparberg M, Simon N, Del Greco F. Intrahepatic cholestasis because of azathioprine. Gastroenterology 1969;57:439-441.
82. DePinto RA, Goldberg CS, Lefkowitch JH. Azathioprine and the liver: Evidence favoring idiosyncratic, mixed cholestatic-hepatocellular injury in humans. Gastroenterology 1984;86: 162-165.
83. Sterneck M, Wiesner R, Ascher N, Roberts J, Ferrell L, Ludwig J, Lake J. Azathioprine hepatotoxicity after liver transplantation. Hepatology 1991;14:806-810.
84. Gane E, Portmann BC, Saxena R, Wong P, Ramage J, Williams R. Nodular regenerative hyperplasia of the liver graft after liver transplantation. Hepatology 1994;20:88-94.
85. Kowdley KV, Keeffe EB, Fawaz KA. Prolonged cholestasis because of trimethoprim sulfamethoxazole. Gastroenterology 1992;102:2148-2150.
86. Yao F, Behling CA, Saab S, Li S, Hart M, Lyche KD. Trimethoprim-sulfamethoxazole-induced vanishing bile duct syndrome. Am J Gastroenterol 1997;92:167-169.
87. Moser MA, Wall WJ. Management of biliary problems after liver transplantation. Liver Transpl 2001;7:S46-S52.
88. Ludwig J, Hashimoto E, Porayko M, Themeau TM. Failed allografts and causes of death after orthotopic liver transplantation from 1985 to 1995: Decreasing prevalence of irreversible hepatic allograft rejection. Liver Transpl Surg 1996;2:185-191.
89. Wiesner RH, Ludwig J, van Hoek B, Krom RAF. Current concepts in cell-mediated hepatic allograft rejection leading io ductopenia and liver failure. Hepatology 1991;14:721-729.
90. Candinas D, Gunson B, Nightingale P, Hubscher C, MacMaster P, Neuberger J. Sex mismatch as a risk factor for chronic rejection of liver grafts. Lancet 1995;346:1117-1121.
91. Lautenschlager I, Hockerstedt K, Jalanko H, Loginov R, Salmela K, Taskinen E, Ahonen J. Persistent cytomegalovirus in liver allografts with chronic rejection. Hepatology 1997;25: 190-194.
92. Demetris AJ, Murase N, Ye Q, Galvao FH, Richert C, Saad R, et al. Analysis of chronic rejection and obliterature arteriopathy. Possible contributions of donor antigen-presenting cells and lymphatic disruption. Am J Pathol 1997;150:563-578.
93. Gouw AS, van der Heuvel MC, vanden Berg AP, Slooff MJ, de Jong KP, Poppema S. The significance of parenchymal changes of acute cellular rejection in predicting chronic liver graft rejection. Transplantation 2002;73:243-247.
94. Langas AN, Marujo W, Stratta RJ, Wood RP, Shaw BW. Vascular complications after orthotopic liver transplantation. Am J Surg 1991;161:76-82.
95. Sanchez-Bueno F, Robles R, Ramirez P, Acosta F, Rodriguez JM, Lujan J, et al. Hepatic artery complications after liver transplantation. Clin Transplant 1994;8:399-404.
96. Stevens LH, Emond JC, Piper JB, Heffron TG, Thistlethwaite JR, Whitington PE, Broelsch CE. Hepatic artery thrombosis in infants. A comparison of whole livers, reduced-size grafts, and grafts from living-related donors. Transplantation 1992; 53:396-399.
97. Mazzaferro V, Esquivel CO, Makowka L, Belle S, Kahn D, Koneru B, et al. Hepatic artery thrombosis after pediatric liver transplantation: A medical or surgical event? Transplantation 1989;47:971-977.
98. Rabkin JM, Orloff SL, Corless CL, Benner KG, Flora KD, Rosen HR, et al. Hepatic allograft abscess with hepatic arterial thrombosis. Am J Surg 1998;175:354-359.
99. Yanaga K, Lebeau G, Marsh JW, Gordon RD, Makowka L, Tzakis AG, et al. Hepatic artery reconstruction for hepatic artery thrombosis after orthotopic liver transplantation. Arch Surg 1990;125:628-631.
100. Sheiner PA, Varma CV, Guarrera JV, Cooper J, Garatti M, Emre S, et al. Selective revascularization of hepatic artery thrombosis after liver transplantation improves patient and allograft survival. Transplantation 1997;64:1295-1299.
101. Valente JF, Alonso MH, Weber FL, Hanto DW. Late hepatic artery thrombosis in liver allograft recipients is associated with intrahepatic biliary necrosis. Transplantation 1996;61:61-65.
102. Bhattacharjya S, Gunson BK, Mirza DF, Mayer DA, Buckels JA, McMaster P, Neuberger JM. Delayed hepatic artery thrombosis in adult orthotopic liver transplantation - A 12-year experience. Transplantation 2001;71:1592-1596.
103. Abbasoglu O, Levy MF, Vodapally MS, Goldstein RM, Husberg BS, Gonwa TA, Klintmalm GB. Hepatic artery stenosis after liver transplantation-incidence, presentation, treatment, and long term outcome. Transplantation 1997;63:250-255.
104. Sidhu PS, Ellis SM, Karani JB, Ryan SM. Hepatic artery stenosis after liver transplantation: Significance of the tardus parvus waveform and the role of microbubble contrast media in the detection of a focal stenosis. Clin Radiol 2002;57:789-799.
105. Starzl TE, Iwatsuki S, Van Thiel DH, Gartner JC, Zitelli BJ, Malatack JJ, et al. Evolution of liver transplantation. Hepatology 1982;2:614-636.
106. Demetris AJ, Jaffe R, Tzakis A, Ramsey G, Todo S, Belle S, et al. Antibody-mediated rejection of human orthotopic liver allografts: A study of liver transplantation across ABO blood group barriers. Am J Pathol 1988;132:489-502.
107. Sanchez-Urdazpal L, Batts K, Gores GJ, Moore SB, Sterioff S, Wiesner RH, Krom RA. Increased bile duct complications in liver transplantation across the ABO barrier. Ann Surg 1993; 218:152-158.
108. Lo CM, Shaked A, Busuttil RW. Risk factors for liver transplantation across the ABO barrier. Transplantation 1994;58: 543-547.
109. Nakanuma Y, Sasaki M. Expression of blood group related antigens in the intrahepatic biliary tree and hepatocytes in normal livers and various hepatobiliary diseases. Hepatology 1989; 2:174-178.
110. Fishbein TM, Emre S, Guy SR, Sheiner PA, Kim LH, Schwartz ME, Miller CM. Safe transplantation of blood type A2 livers to blood type 0 recipients. Transplantation 1999;67:1071-1073.
111. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-1847.
112. Todo S, Demetris AJ, van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991;13:619-629.
113. Lau JY, Bain VG, Davies SE, O'Grady JG, Alberti A, Alexander GJ, Williams R. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology 1992; 102:956-962.
114. Harrison RF, Davies MH, Goldin RD, Hubscher SG. Recurrent hepatitis B in liver allografts: A distinctive form of rapidly developing cirrhosis. Histopathology 1993;23:21-28.
115. Al Faraidy K, Yoshida EM, Davis JE, Vartanian RK, Anderson FH, Steinbrecher UP. Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine. Transplantation 1997;64:926-928.
116. Papatheodoridis GV, Sevastianos V, Burroughs AK. Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transplant 2003;3:250-258.
117. Walsh KM, Woodall T, Lamy P, Wight DG, Bloor S, Alexander GJ. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistance hepatitis B virus. Gut 2001;49:436-440.
118. Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992;103:317-322.
119. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334: 815-820.
120. Schluger LK, Sheiner PA, Thung SN, Lau JY, Min A, Wolf DC, et al. Severe recurrent cholestatic hepatitis C after orthotopic liver transplantation. Hepatology 1996;23:971-976.
121. Deshpande V, Burd E, Aardema KL, Ma CK, Moonka DK, Brown KA, et al. High levels of hepatitis C virus RNA in native livers correlate with the development of cholestatic hepatitis in liver allografts and a poor outcome. Liver Transpl 2001;7:118-124.
122. Taga SA, Washington MK, Terrault N, Wright TL, Somberg KA, Ferrell LD. Cholestatic hepatitis C in liver allografts. Liver Transpl Surg 1998;4:304-310.
123. Pessoa MG, Bzowej N, Berenguer M, Phung Y, Kim M, Ferrell L, et al. Evolution of hepatitic C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Hepatology 1999;30:1513-1520.
124. Bernard PH, Le Bail B, Rullier A, Trimoulet P, Neau-Cransac M, Balabaud C, Bioulac-Sage P. Recurrence and accelerated progression of hepatitis C after liver transplantation. Semin Liver Dis 2000;20:533-538.
125. Doughty AL, Painter DM, McCaughan GW. Post-transplant quasispecies pattern remains stable over time in patients with recurrent cholestatic hepatitis because of hepatitis C virus. J Hepatol 2000;32:126-134.
126. Cotler SJ, Taylor SL, Gretch DR, Brenner MP, Rizk R, Perkins JD, Carithers RL. Hyperbilirubinemia and cholestatic liver injury in hepatitis C-infected liver transplant recipients. Am J Gastroenterol 2000;95:753-759.
127. Neuberger J. Recurrent primary biliary cirrhosis. Liver Transpl 2001;7:596-599.
128. Balan V, Batts KP, Porayko MK, Krom RA, Ludwig J, Wiesner RH. Histologic evidence of recurrence of primary biliary cirrhosis after liver transplantation. Hepatology 1993;18:1392-1398.
129. Hubscher SG, Elias E, Buckels JA, Mayer AD, McMaster P, Neuberger JM. Primary biliary cirrhosis. Histologic evidence of disease recurrence after liver transplantation. J Hepatol 1993; 18:173-184.
130. Hashimoto E, Shimada M, Noguchi S, Taniai M, Tokushige, Hayashi N, et al. Disease recurrence after living liver transplantation for primary biliary cirrhosis: A clinical and histologic follow-up study. Liver Transpl 2001;7:588-595.
131. Dmitrewski J, Hubscher SG, Mayer AD, Neuberger JM. Recurrence of primary biliary cirrhosis in the liver allograft: The effect of immunosuppression. J Hepatol 1996;24:253-257.
132. Narumi S, Roberts JP, Emond JC, Lake J, Asher NL. Liver transplantation of sclerosing cholangitis. Hepatology 1995;22: 451-457.
133. Sheng R, Campbell WL, Zajko AB, Baron RL. Cholangiographic features of biliary strictures after liver transplantation for primary sclerosing cholangitis: Evidence of recurrent disease. Am J Roentgenol 1996;66:1300-1306.
134. Graziadei IW, Wiesner RH, Batts KP, Marotta PJ, LaRusso NF, Porayko MK, et al. Recurrence of primary sclerosing cholangitis after liver transplantation. Hepatology 1999;29: 1050-1056.
135. Jeyarajah DR, Netto GJ, Lee SP, Testa G, Abbasoglu O, Husberg BS, et al. Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: Is chronic rejection part of the disease process? Transplantation 1998;66:1300-1306.
136. Graziadei IW, Wiesner RH, Marotta PJ, Porayko MK, Hay JE, Charlton MR, et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999;30:1121-1127.
137. Poon R, Poon RE. Ursodeoxycholic acid therapy for chronic cholestatic conditions in adults and children. Pharmacol Ther 1995;66:1-15.
138. Soderdahl G, Nowak G, Duraj F, Wang FH, Einarsson C, Ericzon BG. Ursodeoxycholic acid increased bile flow and affects bile composition in the early postoperative phase after liver transplantation. Transpl Int 1998;11:5231-5238.
139. Barnes D, Talenti D, Cammell G, Goormastic M, Farquhar L, Henderson M, et al. A randomized clinical trial of ursodeoxycholic acid as adjuvant treatment to prevent liver transplant rejection. Hepatology 1997;26:853-857.